A PHASE III, DOUBLE-BLIND, RANDOMIZED PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFECTS OF DALCETRAPIB ON CARDIOVASCULAR (CV) RISK IN A GENETICALLY DEFINED POPULATION WITH A RECENT ACUTE CORONARY SYNDROME (ACS): THE DAL-302 (DAL-GENE-2) TRIAL
- Registry ID
- DAL-302
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- DALCOR PHARMACEUTICALS CANADA INC.
- Start date
- 2023-10-02
- Last update
- 2023-04-25
Conditions
Related clinical trials
- A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE EFFICACY
AND SAFETY OF EARLY IN HOSPITAL INITIATION OF INCLISIRAN TREATMENT IN PATIENTS
WITH ACUTE CORONARY SYNDROMES: VICTORION - RIDES
- OPEN-LABEL, SEQUENTIAL-DOSE ESCALATION/DE-ESCALATION TRIAL TESTING MT1002 IN PATIENTS UNDERGOING PCI DUE TO ACUTE CORONARY SYNDROME WITH NSTEMI
- A PHASE III, DOUBLE-BLIND, RANDOMIZED PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFECTS OF DALCETRAPIB ON CARDIOVASCULAR (CV) RISK IN A GENETICALLY DEFINED POPULATION WITH A RECENT ACUTE CORONARY SYNDROME (ACS): THE DAL-GENE TRIAL
- A PHASE IB STUDY OF DUVALUMAB (MEDI-4736) WITH OR WITHOUT TREMELIMUMAB IN PATIENTS WITH ADVANCED INCURABLE SOLID MALIGNANCIES RECEIVING STANDARD CHEMOTHERAPY REGIMENS
- A PLACEBO-CONTROLLED, DOUBLE-BLIND, RANDOMIZED TRIAL TO COMPARE THE EFFECT OF TREATMENT ON PLAQUE BURDEN AS DETERMINED BY IVUS AND TO EVALUATE THE EFFICACY, PK, SAFETY, AND TOLERABILITY OF MDCO-216 GIVEN AS MULTIPLE WEEKLY INFUSIONS IN SUBJECTS WITH A RECENT ACUTE CORONARY SYNDROME
View on source registry